Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyumjev vs Humalog for Recovery from Hyperglycemia in T1DM
NCT04276207Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Missed Meal Bolus and Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Pump Suspension. Started Feb 2020; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04276207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276207.